Biocept investor relations material

Biocept, Inc., is an early stage molecular oncology diagnostic company developing and commercializing proprietary circulating tumor cell and circulating tumor nucleic acid assays utilizing a standard blood sample. Biocept's multi-targeted tests will provide oncologists and their patients with valuable information that may affect the course of treatment decision making in non-small cell lung cancer (NSCLC), breast cancer, colorectal cancer (CRC), melanoma and other solid tumors. The company's initial efforts are focused on CS-36, a test to detect 31 NSCLC mutations, eight PI3K pathway mutations and an EGFR mutation in circulating tumor cells from patients' blood. Biocept is also pursuing additional indications for use of its CTC assay for detecting malignant circulating tumor cells. The company is based in San Diego, California.